BioAtla, Inc.
Edit

BioAtla, Inc.

https://www.bioatla.com/
Last activity: 27.03.2025
Active
Categories: ActiveDevelopmentDrugEngineeringManufacturingOwnPlatformProduct
BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our Conditionally Active Biologics (CAB) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. This improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. BioAtla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
Followers
1.65K
Mentions
32
Employees: 51-200
Total raised: $147.5M
Founded date: 2007
LinkedIn
Email

Investors 1

Funding Rounds 3

DateSeriesAmountInvestors
03.08.2020Series D$72.5M-
11.01.2016-$45M-
11.06.2015-$30M-

Mentions in press and media 32

DateTitleDescription
27.03.2025BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent ProgressCAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overal...
01.10.2024Michael Burry buys 634,000 shares of this $1 penny stockWhen Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice. His hedge fund, Scion Asset Management, acquired 633,959 shares of BioAtla (NASDAQ: BCAB) for $1.3...
23.09.2024BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodyContext to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 millio...
23.09.2024BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodyContext to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 millio...
07.03.2024BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting-
04.11.2022BioAtla Announces $65 Million Underwritten Offering of its Common Stock/EIN News/ -- SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment...
04.11.2022BioAtla Announces $65 Million Underwritten Offering of its Common Stock-
11.01.2022BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid ...SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entere...
11.01.2022BioAtla : JPM Presentation 2022.pdfTRANSFORMING CANCER THERAPY January 2022 ` Healthcare Conference Important Notices & Disclaimers This presentation (the "Presentation") relates to a potential private placement of BioAtla, Inc.'s ("we", "us"...
16.11.2021BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business UpdateSAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In